Jun 21, 2019 - We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
Jun 19, 2019 - Alexion (ALXN) receives approval in Japan for its long-acting C5 complement inhibitor, Ultomiris, for the PHN indication.
Jun 19, 2019 - There has been a flurry of M&A deal announcements this year in the drug industry. Here we discuss three big drug/biotech companies, which may make the next M&A move.
Jun 18, 2019 - Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Jun 17, 2019 - Novartis (NVS) announces positive data on CML drugs and biosimilar Hyrimoz.
Jun 17, 2019 - Regeneron (REGN) reports positive early-stage data on REGN1979 in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma.
Jun 16, 2019 - The clock is ticking for Celgene's acquisition by Bristol-Myers Squibb. But is Celgene still a stock worth buying?
Jun 14, 2019 - Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.
Jun 12, 2019 - Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Jun 12, 2019 - The large-cap pharma industry is doing well in 2019. Here are three stocks from the space that investors may consider betting on.